Yoda Pharmaceuticals Inc. (7829.TWO)
Taipei Exchange · TWD · Healthcare · Drug Manufacturers - Specialty & Generic
NT$51.20 (-3.21%) as of
Key statistics
- Market cap
- 5.09B
- EPS (TTM)
- -4.09
- Dividend yield
- 0.00%
- 52-week range
- 36.20 – 66.20
- Profit margin
- 0.00%
- Volume
- 34.02k
About Yoda Pharmaceuticals Inc.
Yoda Pharmaceuticals Inc., an AI-driven company, focuses on development of drugs targeting central nervous system disorders. The company's flagship drug, YA-101 is in Phase 2 clinical trial for the treatment of multiple system atrophy. It is also involved in the development pipeline includes drugs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions, such as schizophrenia, Alzheimer's disease, Parkinsons disease, Autism, ischemic stroke, and traumatic brain injury. Yoda Pharmaceuticals Inc. was incorporated in 2019 and is based in Grand Cayman, the Cayman Islands.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Grand Cayman, Cayman Islands
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.